Anemia Biotech FibroGen Readies For $124M IPO
Anemia treatment developer FibroGen. Inc. fine-tuned its initial public offering plans Thursday, setting the stage to raise about $124 million and become the largest biotech by diluted market capitalization in a...To view the full article, register now.
Already a subscriber? Click here to view full article